Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukemia (INIM)
NCT02949570Phase 2Unknown
- Sponsor
- Hybrigenics
- Start
- Feb 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inecalcitol in Chronic Myeloid Leukemia (CML), sponsored by Hybrigenics. Primary endpoint: Proportion of Responders at 12 months. Status: unknown.
02
Drugs
inecalcitol
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT02949570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949570.